JP2001512748A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2001512748A5 JP2001512748A5 JP2000506324A JP2000506324A JP2001512748A5 JP 2001512748 A5 JP2001512748 A5 JP 2001512748A5 JP 2000506324 A JP2000506324 A JP 2000506324A JP 2000506324 A JP2000506324 A JP 2000506324A JP 2001512748 A5 JP2001512748 A5 JP 2001512748A5
- Authority
- JP
- Japan
- Prior art keywords
- influenza
- antigen
- cell
- vaccine
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000427 antigen Substances 0.000 description 26
- 102000036639 antigens Human genes 0.000 description 26
- 108091007433 antigens Proteins 0.000 description 26
- 206010022000 influenza Diseases 0.000 description 20
- 210000004027 cell Anatomy 0.000 description 11
- 229960005486 vaccine Drugs 0.000 description 11
- 108090000623 proteins and genes Proteins 0.000 description 6
- 239000012634 fragment Substances 0.000 description 5
- 108010052285 Membrane Proteins Proteins 0.000 description 4
- 102000018697 Membrane Proteins Human genes 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 3
- 230000004927 fusion Effects 0.000 description 3
- 108090000765 processed proteins & peptides Proteins 0.000 description 3
- 108091026890 Coding region Proteins 0.000 description 2
- 229940021995 DNA vaccine Drugs 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 101001039853 Sonchus yellow net virus Matrix protein Proteins 0.000 description 2
- 206010046865 Vaccinia virus infection Diseases 0.000 description 2
- 230000002068 genetic effect Effects 0.000 description 2
- 208000007089 vaccinia Diseases 0.000 description 2
- 101710132601 Capsid protein Proteins 0.000 description 1
- 108010041986 DNA Vaccines Proteins 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 102000011931 Nucleoproteins Human genes 0.000 description 1
- 108010061100 Nucleoproteins Proteins 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 1
- 230000002708 enhancing effect Effects 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 210000002443 helper t lymphocyte Anatomy 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 208000002672 hepatitis B Diseases 0.000 description 1
- 230000005847 immunogenicity Effects 0.000 description 1
- 230000002480 immunoprotective effect Effects 0.000 description 1
- 208000037797 influenza A Diseases 0.000 description 1
- 208000037798 influenza B Diseases 0.000 description 1
- 208000037799 influenza C Diseases 0.000 description 1
- 230000021633 leukocyte mediated immunity Effects 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 229920001059 synthetic polymer Polymers 0.000 description 1
- 108010044241 tetanus toxin fragment C Proteins 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 241000712461 unidentified influenza virus Species 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP97202434.3 | 1997-08-05 | ||
| EP97202434 | 1997-08-05 | ||
| PCT/EP1998/005106 WO1999007839A2 (en) | 1997-08-05 | 1998-08-05 | Immunoprotective influenza antigen and its use in vaccination |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009239092A Division JP2010059164A (ja) | 1997-08-05 | 2009-10-16 | 新しい免疫防御性インフルエンザ抗原及びそのワクチン接種への使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2001512748A JP2001512748A (ja) | 2001-08-28 |
| JP2001512748A5 true JP2001512748A5 (https=) | 2006-01-12 |
| JP5132851B2 JP5132851B2 (ja) | 2013-01-30 |
Family
ID=8228624
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000506324A Expired - Lifetime JP5132851B2 (ja) | 1997-08-05 | 1998-08-05 | 新しい免疫防御性インフルエンザ抗原及びそのワクチン接種への使用 |
| JP2009239092A Pending JP2010059164A (ja) | 1997-08-05 | 2009-10-16 | 新しい免疫防御性インフルエンザ抗原及びそのワクチン接種への使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009239092A Pending JP2010059164A (ja) | 1997-08-05 | 2009-10-16 | 新しい免疫防御性インフルエンザ抗原及びそのワクチン接種への使用 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US7732130B2 (https=) |
| EP (1) | EP0996717B1 (https=) |
| JP (2) | JP5132851B2 (https=) |
| AT (1) | ATE312172T1 (https=) |
| AU (1) | AU745951B2 (https=) |
| CA (1) | CA2297786C (https=) |
| DE (1) | DE69832706T2 (https=) |
| DK (1) | DK0996717T3 (https=) |
| ES (1) | ES2255181T3 (https=) |
| WO (1) | WO1999007839A2 (https=) |
Families Citing this family (62)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7731972B1 (en) | 2000-02-04 | 2010-06-08 | Vlaams Interuniversitair Instituut Voor Biotechnologie | Immunoprotective influenza antigen and its use in vaccination |
| CA2297786C (en) | 1997-08-05 | 2011-06-14 | Vlaams Interuniversitair Instituut Voor Biotechnologie | New immunoprotective influenza antigen and its use in vaccination |
| MXPA01005389A (es) | 1998-11-30 | 2003-03-27 | Cytos Biotechnology Ag | Presentacion molecular ordenada de antigenos, metodos de preparacion y uso. |
| GB0008582D0 (en) * | 2000-04-08 | 2000-05-31 | Adprotech Plc | DNA immunization vectors |
| JP4927290B2 (ja) * | 2000-04-14 | 2012-05-09 | ウィスコンシン アルムニ リサーチ ファンデイション | 変異イオンチャンネルタンパク質を含んで成るウイルス |
| EP1282640A2 (en) * | 2000-05-01 | 2003-02-12 | Powderject Vaccines, Inc. | Nucleic acid immunization |
| CA2407897A1 (en) | 2000-05-05 | 2001-11-15 | Cytos Biotechnology Ag | Molecular antigen arrays and vaccines |
| GB0025229D0 (en) * | 2000-10-14 | 2000-11-29 | Adprotech Ltd | Veterinary immunisation vectors |
| US7128911B2 (en) | 2001-01-19 | 2006-10-31 | Cytos Biotechnology Ag | Antigen arrays for treatment of bone disease |
| US7094409B2 (en) | 2001-01-19 | 2006-08-22 | Cytos Biotechnology Ag | Antigen arrays for treatment of allergic eosinophilic diseases |
| US7264810B2 (en) | 2001-01-19 | 2007-09-04 | Cytos Biotechnology Ag | Molecular antigen array |
| US7361352B2 (en) | 2001-08-15 | 2008-04-22 | Acambis, Inc. | Influenza immunogen and vaccine |
| DE60234375D1 (de) | 2001-09-14 | 2009-12-24 | Cytos Biotechnology Ag | VERPACKUNG VON IMMUNSTIMULIERENDEM CpG IN VIRUSÄHNLICHEN PARTIKELN: HERSTELLUNGSVERFAHREN UND VERWENDUNG |
| US7115266B2 (en) | 2001-10-05 | 2006-10-03 | Cytos Biotechnology Ag | Angiotensin peptide-carrier conjugates and uses thereof |
| US7351413B2 (en) | 2002-02-21 | 2008-04-01 | Lorantis, Limited | Stabilized HBc chimer particles as immunogens for chronic hepatitis |
| GB0204154D0 (en) * | 2002-02-22 | 2002-04-10 | Adprotech Ltd | Cat immunisation vectors |
| CA2478973A1 (en) * | 2002-03-13 | 2003-09-25 | Kirin Beer Kabushiki Kaisha | Human monoclonal antibodies to influenza m2 protein and methods of making and using same |
| US7138252B2 (en) | 2002-07-17 | 2006-11-21 | Cytos Biotechnology Ag | Molecular antigen arrays |
| CA2487849A1 (en) | 2002-07-18 | 2004-01-29 | Cytos Biotechnology Ag | Hapten-carrier conjugates comprising virus like particles and uses thereof |
| EP2338510A1 (en) | 2002-07-19 | 2011-06-29 | Novartis Pharma AG | Vaccine compositions containing amyloid beta1-6 antigen arrays |
| AU2004232992A1 (en) * | 2003-04-23 | 2004-11-04 | Wisconsin Alumni Research Foundation | Recombinant influenza viruses holding a mutation in a transmembrane protein gene |
| EP1638601B1 (en) * | 2003-06-23 | 2008-11-19 | Baxter International Inc. | Carrier proteins for vaccines |
| EA200701097A1 (ru) | 2004-11-19 | 2007-10-26 | Висконсин Эламни Рисёч Фаундэйшн | Рекомбинантные векторы вируса гриппа с тандемными транскрипционными единицами |
| EP1819732A2 (en) | 2004-12-06 | 2007-08-22 | Kirin Beer Kabushiki Kaisha | Human monoclonal antibodies to influenza m2 protein and methods of making and using same |
| US20090162400A1 (en) * | 2004-12-21 | 2009-06-25 | Powell Thomas J | Compositions of influenza viral proteins and methods of use thereof |
| US8420102B2 (en) * | 2006-03-07 | 2013-04-16 | Vaxinnate Corporation | Compositions that include hemagglutinin |
| EP1951862B1 (en) * | 2005-11-07 | 2013-07-24 | MicroVAX, LLC | Cd40 ligand fusion protein vaccine |
| PT1968632E (pt) | 2005-12-06 | 2012-07-16 | Yeda Res & Dev | Vacina da gripe melhorada |
| CA2647985C (en) | 2006-03-31 | 2014-12-30 | Warf-Wisconsin Alumni Research Foundation | High titer recombinant influenza viruses for vaccines |
| AU2007297801A1 (en) | 2006-07-14 | 2008-03-27 | Sanofi Pasteur Biologics Co. | Construction of recombinant virus vaccines by direct transposon-mediated insertion of foreign immunologic determinants into vector virus proteins |
| EP2069483A4 (en) | 2006-09-29 | 2010-10-27 | Sanofi Pasteur Biologics Co | RECOMBINANT RHINOVIRAL VECTORS |
| CA2669485C (en) * | 2006-11-15 | 2017-01-03 | Folia Biotech Inc. | Papaya mosaic virus-based vaccines for influenza |
| US9474798B2 (en) | 2007-06-18 | 2016-10-25 | Wisconsin Alumni Research Foundation | Influenza M2 protein mutant viruses as live influenza attenuated vaccines |
| EA017887B1 (ru) | 2007-08-02 | 2013-03-29 | Байондвакс Фармасьютикалз Лтд. | Полимерные мультиэпитопные вакцины против гриппа |
| CA2705461A1 (en) * | 2007-11-12 | 2009-06-11 | The Trustees Of The University Of Pennsylvania | Vaccines against multiple subtypes of influenza virus |
| AU2009236585B2 (en) | 2008-04-18 | 2013-03-07 | Vaxinnate Corporation | Deletion mutants of flagellin and methods of use |
| WO2010012069A1 (en) * | 2008-07-30 | 2010-02-04 | Folio Biotech Inc. | Multivalent vaccines based on papaya mosaic virus and uses thereof |
| EP2168987A1 (en) * | 2008-09-22 | 2010-03-31 | Mucosis B.V. | Multifunctional linker protein containing an antibody against hemagglutinin, a conserved influenza antigen and an immunostimulating carrier binding domain |
| JP5903045B2 (ja) * | 2009-07-31 | 2016-04-13 | パックスバックス， インコーポレイテッド | アデノウイルスに基づくベクター |
| ES2682998T3 (es) | 2009-08-28 | 2018-09-24 | The Chemo-Sero-Therapeutic Research Institute | Vacuna de péptido modificado derivada de M2 de influenza |
| US20110097358A1 (en) * | 2009-10-12 | 2011-04-28 | Techno Vax, Inc. | RESPIRATORY SYNCYTIAL VIRUS (RSV) VIRUS-LIKE PARTICLES (VLPs) |
| EP2493912B1 (en) | 2009-10-26 | 2020-07-29 | Wisconsin Alumni Research Foundation | High titer recombinant influenza viruses with enhanced replication in vero cells |
| WO2011054995A2 (es) | 2009-11-06 | 2011-05-12 | Chimera Pharma, S. L. U. | VACUNAS PROFILACTICAS DE GRIPE A PARTIR DE CAPSIDAS VIRALES DE BIRNAVIRUS CONTENIENDO EL ANTIGENO M2e DEL VIRUS DE LA GRIPE |
| US10130697B2 (en) | 2010-03-23 | 2018-11-20 | Wisconsin Alumni Research Foundation (Warf) | Vaccines comprising mutant attenuated influenza viruses |
| WO2012114323A1 (en) | 2011-02-22 | 2012-08-30 | Biondvax Pharmaceuticals Ltd. | Multimeric multiepitope polypeptides in improved seasonal and pandemic influenza vaccines |
| JP2014527799A (ja) | 2011-08-26 | 2014-10-23 | ダブリュエーアールエフ−ウィスコンシン アラムナイ リサーチ ファウンデーション | 変異型ｐｂ２遺伝子セグメントを有する弱毒化生ワクチンとしてのインフルエンザウイルス |
| US8932598B2 (en) | 2012-08-28 | 2015-01-13 | Vaxinnate Corporation | Fusion proteins and methods of use |
| WO2015009743A1 (en) | 2013-07-15 | 2015-01-22 | Wisconsin Alumni Research Foundation | High titer recombinant influenza viruses with enhanced replication in mdck or vero cells or eggs |
| US10053671B2 (en) | 2014-06-20 | 2018-08-21 | Wisconsin Alumni Research Foundation (Warf) | Mutations that confer genetic stability to additional genes in influenza viruses |
| US10633422B2 (en) | 2015-06-01 | 2020-04-28 | Wisconsin Alumni Research Foundation (Warf) | Influenza virus replication by inhibiting microRNA lec7C binding to influenza viral cRNA and mRNA |
| EP3103474A1 (en) * | 2015-06-12 | 2016-12-14 | Institut Pasteur | Live recombinant measles-m2 virus and its use in eliciting immunity against influenza viruses |
| US9890363B2 (en) | 2015-07-06 | 2018-02-13 | Wisconsin Alumni Research Foundation (Warf) | Influenza virus replication for vaccine development |
| US11197925B2 (en) | 2016-02-19 | 2021-12-14 | Wisconsin Alumni Research Foundation (Warf) | Influenza B virus replication for vaccine development |
| WO2019084310A1 (en) | 2017-10-25 | 2019-05-02 | Yoshihiro Kawaoka | HAS RECOMBINANT INFLUENZA VIRUSES STABILIZED FOR EGG REPLICATION |
| US12343390B2 (en) | 2018-08-07 | 2025-07-01 | Wisconsin Alumni Research Foundation (Warf) | Recombinant biologically contained filovirus vaccine |
| JP7655849B2 (ja) | 2018-08-20 | 2025-04-02 | ウィスコンシン アルムニ リサーチ ファンデイション | ヘマグルチニン（ｈａ）タンパク質内の非ドミナントエピトープに対する免疫応答を誘起するためのベクター |
| EP3914295A2 (en) | 2019-01-23 | 2021-12-01 | Yoshihiro Kawaoka | Mutations that confer genetic stability to additional genes in influenza viruses |
| EP3921413A1 (en) | 2019-02-08 | 2021-12-15 | Wisconsin Alumni Research Foundation (WARF) | Humanized cell line |
| CN114929269A (zh) | 2019-05-01 | 2022-08-19 | 威斯康星校友研究基金会(Warf) | 用于疫苗开发的改进的流感病毒复制 |
| US11807872B2 (en) | 2019-08-27 | 2023-11-07 | Wisconsin Alumni Research Foundation (Warf) | Recombinant influenza viruses with stabilized HA for replication in eggs |
| JP2023511444A (ja) | 2020-01-24 | 2023-03-17 | ウィスコンシン アルムニ リサーチ ファンデイション | 安定化されたｎａを有する組換えインフルエンザウイルス |
| WO2021195410A1 (en) | 2020-03-25 | 2021-09-30 | Wisconsin Alumni Research Foundation (Warf) | Recombinant multivalent influenza viruses |
Family Cites Families (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3919044A (en) | 1973-03-28 | 1975-11-11 | Armour Pharma | Processes for concentrating and purifying viruses and viral antigens |
| NZ219516A (en) * | 1987-02-10 | 1991-02-26 | Wellcome Found | Fusion proteins of hbcag (hepatitis b virus core antigen) |
| JPH06508623A (ja) * | 1991-06-19 | 1994-09-29 | エス・アール・アイ・インターナシヨナル | 抗ウィルス剤としてのインフルエンザウィルスのｍ−蛋白質ペプチド |
| FR2695563B1 (fr) | 1992-09-11 | 1994-12-02 | Pasteur Institut | Microparticules portant des antigènes et leur utilisation pour l'induction de réponses humorales ou cellulaires. |
| WO1994025060A1 (en) * | 1993-04-27 | 1994-11-10 | Ladd Anna E | Immunogenic lhrh peptide constructs and synthetic universal immune stimulators for vaccines |
| US5759551A (en) | 1993-04-27 | 1998-06-02 | United Biomedical, Inc. | Immunogenic LHRH peptide constructs and synthetic universal immune stimulators for vaccines |
| CA2168459C (en) * | 1993-07-30 | 2002-10-01 | Mohammed Anjam Khan | Fusion proteins containing the c-terminal of tetanus toxin linked to a heterologous protein |
| US5691189A (en) * | 1994-01-19 | 1997-11-25 | Bristol-Myers Squibb Company | Saccharomyces cerevisiae expressing M2 protein of influenza A virus |
| GB9424631D0 (en) * | 1994-12-06 | 1995-01-25 | Lynxvale Ltd | Modulating the immune response |
| GB9521568D0 (en) * | 1995-10-20 | 1995-12-20 | Lynxvale Ltd | Delivery of biologically active polypeptides |
| JP4484969B2 (ja) | 1996-11-26 | 2010-06-16 | ヌベンタ バイオファーマスティカル コーポレイション | ストレスタンパク質を含む組成物を使用する免疫応答 |
| CA2297786C (en) | 1997-08-05 | 2011-06-14 | Vlaams Interuniversitair Instituut Voor Biotechnologie | New immunoprotective influenza antigen and its use in vaccination |
| US6169175B1 (en) | 1997-08-06 | 2001-01-02 | Centers For Disease Control And Prevention | Preparation and use of recombinant influenza A virus M2 construct vaccines |
| US20020015951A1 (en) | 2000-01-06 | 2002-02-07 | Bader Joel S. | Method of analyzing a nucleic acid |
-
1998
- 1998-08-05 CA CA2297786A patent/CA2297786C/en not_active Expired - Lifetime
- 1998-08-05 EP EP98946321A patent/EP0996717B1/en not_active Revoked
- 1998-08-05 AT AT98946321T patent/ATE312172T1/de active
- 1998-08-05 AU AU93416/98A patent/AU745951B2/en not_active Expired
- 1998-08-05 DK DK98946321T patent/DK0996717T3/da active
- 1998-08-05 ES ES98946321T patent/ES2255181T3/es not_active Expired - Lifetime
- 1998-08-05 DE DE69832706T patent/DE69832706T2/de not_active Expired - Lifetime
- 1998-08-05 WO PCT/EP1998/005106 patent/WO1999007839A2/en not_active Ceased
- 1998-08-05 JP JP2000506324A patent/JP5132851B2/ja not_active Expired - Lifetime
-
2006
- 2006-03-14 US US11/374,922 patent/US7732130B2/en active Active
-
2009
- 2009-10-16 JP JP2009239092A patent/JP2010059164A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2001512748A5 (https=) | ||
| CA2297786A1 (en) | New immunoprotective influenza antigen and its use in vaccination | |
| US11938221B2 (en) | Multivalent nanoparticle-based vaccines | |
| JP7465310B2 (ja) | 多用途性且つ効率的な遺伝子発現のためのｒｎａレプリコン | |
| JP7788787B2 (ja) | 遺伝子発現増強のための組成物および方法 | |
| Moser et al. | Virosomal adjuvanted antigen delivery systems | |
| Arnold et al. | Protective vaccination against infectious bursal disease virus with whole recombinant Kluyveromyces lactis yeast expressing the viral VP2 subunit | |
| EP2204187A1 (en) | Human flu vaccine containing four influenza peptides | |
| US20090304735A1 (en) | Immunogenic Compositions | |
| JPH07501707A (ja) | キメラ免疫原 | |
| AU682344B2 (en) | Recombinant poxvirus and streptococcal M protein vaccine | |
| Plotkin | Six revolutions in vaccinology | |
| US5882650A (en) | Cross-reactive influenza A immunization | |
| US20200079838A1 (en) | Mosaic chimeric viral vaccine particle | |
| CN118750594B (zh) | 一种二价猪口蹄疫mRNA疫苗及其制备方法和应用 | |
| WO2002074920A3 (en) | A replication-defective alphavirus vaccine linking antigen with an immunogenicity-potentiating polypeptide and a method of delivery the same | |
| Yang et al. | Strategies for developing self-assembled nanoparticle vaccines against SARS-CoV-2 infection | |
| Wu et al. | Nanovaccines to combat virus‐related diseases | |
| Skrastina et al. | Chimeric derivatives of hepatitis B virus core particles carrying major epitopes of the rubella virus E1 glycoprotein | |
| Khawaja et al. | Enhanced magnitude and breadth of neutralizing humoral response to a DNA vaccine targeting the DHBV envelope protein delivered by in vivo electroporation | |
| Beauverger et al. | Measles virus hemagglutinin induces an Ld-restricted CD8+ cytotoxic T lymphocyte response to two specific epitopes | |
| Zuckerman | Subunit, recombinant and synthetic hepatitis B vaccines | |
| CA2090005C (en) | Cross-reactive influenza a immunization | |
| Le Grand et al. | Recombinant vaccines: development, production, and application | |
| Cogan | Towards new vaccines against virus infection:(European Molecular Biology Organization Workshop) 20–23 June 1983, Espoo, Finland |